Edgewise Therapeutics, Inc.
EWTX
株式のランク
#3882
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
株価
$39.70
時価総額
$4.27B
変化（1日）
-0.12%
変化（1年）
155.98%
国
US
取引 Edgewise Therapeutics, Inc. (EWTX)
カテゴリー
Healthcare
Edgewise Therapeutics, Inc.（EWTX）の株価履歴
終値の最高値: $38.97 （2026-10-01）
終値の最安値: $32.43 （2021-03-01）
終値の最安値: $32.43 （2021-03-01）
Edgewise Therapeutics, Inc. の株価履歴（2021 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $136.29 | -4.85% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
